Ghent

Konica Minolta First to Launch Presses with EFI Fiery FS500 Pro Software and New Hardware

Retrieved on: 
Monday, May 2, 2022
Command, GWG, Fire, Ernst & Young Entrepreneur of the Year Award, Konica Minolta, Textile, Solution, Technology, Pantone, YouTube, Twitter, Color, Partnership, EFI, Industry, Pre-flight, LinkedIn, Reproduction, Printing, Automation, Senior, Compliance, Efficiency, BLI, Ghent, Loyalty business model, MFP, Name, Electronics, DFE, GLOBE, Russian Imperial Guard, PDF, Dow Jones, Department, Marketing, 3D printing, Music, Facebook

The new solutions EFI and Konica Minolta are announcing include:

Key Points: 
  • The new solutions EFI and Konica Minolta are announcing include:
    EFI Fiery IC-317 and IC-419 v2 DFEs that will drive the Konica Minolta AccurioPress C4080/C4070/C4065 printers.
  • The new Fiery FS500 Pro server platform offers many benefits to print service providers operating Konica Minolta presses, including:
    Even faster processing time.
  • The EFI Fiery DFEs are the fastest in the industry and just became even faster with FS500 Pro.
  • Konica Minolta is a registered trademark of Konica Minolta, Inc. AccurioPress is a trademark of Konica Minolta, Inc. Pantone is a registered trademark and the property of Pantone LLC.

MRM Health Announces First Patient Dosed with Next Generation Live Microbiome Consortia Therapeutic MH002 in Phase 1b/2a Study in Patients with Ulcerative Colitis

Retrieved on: 
Wednesday, December 8, 2021
Health, Rectum, Colon, GLOBE, UZ Leuven, Technology, Lists of diseases, Therapy, Dysbiosis, Inflammation, Immunomodulation, Safety, Inflammatory bowel disease, UC, Patient, Spondyloarthropathy, Doctor of Philosophy, MD, Immunosuppression, Autoimmune disease, IBD, MRM, Abdominal pain, Mesalazine, Compliance, DuPont, Pharmaceutical industry, Medical device, Vaccine, Fine chemical

GHENT, Belgium, Dec. 08, 2021 (GLOBE NEWSWIRE) -- MRM Health, a clinical-stage biopharmaceutical company developing next-generation live microbiome consortia therapeutics, announced that the first patient received MH002 in a phase 1b/2a multi-center clinical trial in mild-to-moderate Ulcerative Colitis.

Key Points: 
  • GHENT, Belgium, Dec. 08, 2021 (GLOBE NEWSWIRE) -- MRM Health, a clinical-stage biopharmaceutical company developing next-generation live microbiome consortia therapeutics, announced that the first patient received MH002 in a phase 1b/2a multi-center clinical trial in mild-to-moderate Ulcerative Colitis.
  • We are very excited about this next step in the development of MH002 in Ulcerative Colitis, said Sam Possemiers, Ph.D., Chief Executive Officer of MRM Health.
  • MRM Healths MH002-UC-201 study is a multi-center, double-blind, randomized, placebo-controlled trial in multiple clinical sites in Belgium, Poland and Czech Republic and will enrol 45 mild-to-moderate UC patients.
  • MH002 is entering a Phase 1b/2a study in patients with mild-to-moderate ulcerative colitis in Q4 2021.

MRM Health Receives CTA Approval for Phase 1b/2a Trial with Next Generation Optimized Consortium Therapeutic MH002 in Ulcerative Colitis

Retrieved on: 
Tuesday, September 28, 2021
Ulcerative colitis, Medication, Compliance, IBD, Immunosuppression, UC, Therapy, DuPont, Inflammation, Colon, FAMHP, Health, Abdominal pain, Patient, Mesalazine, Immunomodulation, Rectum, Dysbiosis, MD, Federal agency, Spondyloarthropathy, CGMP, MRM, Lists of diseases, Inflammatory bowel disease, Safety, Autoimmune disease, Doctor of Philosophy, UZ Leuven, GLOBE, Federal Agency for Medicines and Health Products, Pharmaceutical industry, Vaccine

MH002 is the first rationally-designed consortium therapy, in which key disease-driving mechanisms guide therapeutic microbial strain selection, to enter clinical studies in patients.

Key Points: 
  • MH002 is the first rationally-designed consortium therapy, in which key disease-driving mechanisms guide therapeutic microbial strain selection, to enter clinical studies in patients.
  • MH002 is produced using MRM Healths breakthrough scalable, robust, and standardized cGMP manufacturing platform, overcoming past microbiome challenges in manufacturing multi-strain consortia of uniform composition.
  • MRM Healths Phase 1b/2a study is a multi-center, double-blind, randomized, placebo-controlled trial which will enroll 45 mild-to-moderate UC patients.
  • MRM Health NV, Ghent, Belgium, is a biopharmaceutical company focused on the development of next-generation optimized consortium therapeutics based on the human microbiome.

Deliverect launches "Hidden Gems" contest to support SMB restaurants

Retrieved on: 
Thursday, July 15, 2021
Restaurant, Menu, Food delivery

Following a year that saw a food delivery boom in response to the pandemic, Deliverect is continuing to support the restaurants we all know and love by welcoming its SMB customers to submit their online ordering "hidden gem" menu item.

Key Points: 
  • Following a year that saw a food delivery boom in response to the pandemic, Deliverect is continuing to support the restaurants we all know and love by welcoming its SMB customers to submit their online ordering "hidden gem" menu item.
  • With the "Hidden Gems" contest, the company is continuing its mission to help restaurants further their online growth and launch new initiatives.
  • From small family owned establishments to large global chains, restaurants all over the world rely on Deliverect for online order management.
  • To participate in the contest, Deliverect SMB restaurants can upload a photo of their hidden gem to the contest voting site , along with a description of the dish.

Deliverect launches "Hidden Gems" contest to support SMB restaurants

Retrieved on: 
Thursday, July 15, 2021
Restaurant, Menu, Food delivery

Following a year that saw a food delivery boom in response to the pandemic, Deliverect is continuing to support the restaurants we all know and love by welcoming its SMB customers to submit their online ordering "hidden gem" menu item.

Key Points: 
  • Following a year that saw a food delivery boom in response to the pandemic, Deliverect is continuing to support the restaurants we all know and love by welcoming its SMB customers to submit their online ordering "hidden gem" menu item.
  • With the "Hidden Gems" contest, the company is continuing its mission to help restaurants further their online growth and launch new initiatives.
  • From small family owned establishments to large global chains, restaurants all over the world rely on Deliverect for online order management.
  • To participate in the contest, Deliverect SMB restaurants can upload a photo of their hidden gem to the contest voting site , along with a description of the dish.

ExeVir and Mithra announce manufacturing collaboration for innovative Covid-19 treatments

Retrieved on: 
Thursday, July 15, 2021
Mithra, Yazatas, Fill and finish, Economic sectors, Economic taxonomy

ExeVir launched less than one year ago and has made tremendous progress in building the company and an innovative pipeline.

Key Points: 
  • ExeVir launched less than one year ago and has made tremendous progress in building the company and an innovative pipeline.
  • Under the terms of the collaboration, Mithra will be responsible for upscalingand manufacturing services for filling the drug substance in support of clinical and commercial supply.
  • Torsten Mummenbrauer, CEO of ExeVir Bio, said: "We are very pleased to collaborate with Mithra which has built a cutting-edge new fill and finish manufacturing facility.
  • Renaat Baes, Chief Manufacturing Officer of Mithra, commented:"We are absolutely thrilled to enter into this collaboration agreement with ExeVir, who is developing promising innovative Covid-19 treatments.

eTheRNA immunotherapies and Ghent University Announce mRNA Delivery Collaboration and License Agreement

Retrieved on: 
Tuesday, July 13, 2021
Lipids, Solid lipid nanoparticle, Ghent

NIEL and GHENT, Belgium, July 13, 2021 /PRNewswire/ --eTheRNA immunotherapies NV ('eTheRNA'), a clinical-stage company developing mRNA immunotherapies for the treatment of cancer and infectious diseases, announces a collaboration and license agreement with Ghent University.

Key Points: 
  • NIEL and GHENT, Belgium, July 13, 2021 /PRNewswire/ --eTheRNA immunotherapies NV ('eTheRNA'), a clinical-stage company developing mRNA immunotherapies for the treatment of cancer and infectious diseases, announces a collaboration and license agreement with Ghent University.
  • Steven Powell, CEO at eTheRNA immunotherapies commented: "We are delighted to collaborate with the laboratory of Prof. De Geest from Ghent University with their valuable, combined expertise in chemistry, nanotechnology and immunology.
  • This collaboration and license agreement gives us access to lipid nanoparticles with enhanced thermostability and improved safety profiles.
  • Prof. Bruno De Geest, Ghent University commented: "I am delighted that my long-lasting collaboration with Dr. Stefaan De Koker from eTheRNA immunotherapies has culminated in this successful technology platform.

eTheRNA immunotherapies and Ghent University Announce mRNA Delivery Collaboration and License Agreement

Retrieved on: 
Tuesday, July 13, 2021
Lipids, Solid lipid nanoparticle, Ghent

NIEL and GHENT, Belgium, July 13, 2021 /PRNewswire/ --eTheRNA immunotherapies NV ('eTheRNA'), a clinical-stage company developing mRNA immunotherapies for the treatment of cancer and infectious diseases, announces a collaboration and license agreement with Ghent University.

Key Points: 
  • NIEL and GHENT, Belgium, July 13, 2021 /PRNewswire/ --eTheRNA immunotherapies NV ('eTheRNA'), a clinical-stage company developing mRNA immunotherapies for the treatment of cancer and infectious diseases, announces a collaboration and license agreement with Ghent University.
  • Steven Powell, CEO at eTheRNA immunotherapies commented: "We are delighted to collaborate with the laboratory of Prof. De Geest from Ghent University with their valuable, combined expertise in chemistry, nanotechnology and immunology.
  • This collaboration and license agreement gives us access to lipid nanoparticles with enhanced thermostability and improved safety profiles.
  • Prof. Bruno De Geest, Ghent University commented: "I am delighted that my long-lasting collaboration with Dr. Stefaan De Koker from eTheRNA immunotherapies has culminated in this successful technology platform.

Darling Ingredients Announces Commissioning of Production Facility in Ghent Belgium

Retrieved on: 
Wednesday, July 15, 2020
Structural proteins, Branches of biology, Geography of Belgium, Chemical substances, Skin care, Collagen, Gelatin, Ghent, Rousselot

IRVING, Texas, July 15, 2020 /PRNewswire/ --Darling Ingredients Inc. (NYSE: DAR), today announced that its Rousselot business has successfully commissioned collagen peptides production at its Ghent Belgium location.

Key Points: 
  • IRVING, Texas, July 15, 2020 /PRNewswire/ --Darling Ingredients Inc. (NYSE: DAR), today announced that its Rousselot business has successfully commissioned collagen peptides production at its Ghent Belgium location.
  • Ghent is one of the main Rousselot collagen production sites and is exclusively producing porcine collagen.
  • "We are excited to announce the commissioning of this production facility in Ghent," said Randall C. Stuewe, Chairman and Chief Executive Officer of Darling Ingredients.
  • The Company sells its products domestically and internationally and operates within three industry segments: Feed Ingredients, Food Ingredients and Fuel Ingredients.

Darling Ingredients Announces Commissioning of Production Facility in Ghent Belgium

Retrieved on: 
Wednesday, July 15, 2020
Structural proteins, Branches of biology, Geography of Belgium, Chemical substances, Skin care, Collagen, Gelatin, Ghent, Rousselot

IRVING, Texas, July 15, 2020 /PRNewswire/ --Darling Ingredients Inc. (NYSE: DAR), today announced that its Rousselot business has successfully commissioned collagen peptides production at its Ghent Belgium location.

Key Points: 
  • IRVING, Texas, July 15, 2020 /PRNewswire/ --Darling Ingredients Inc. (NYSE: DAR), today announced that its Rousselot business has successfully commissioned collagen peptides production at its Ghent Belgium location.
  • Ghent is one of the main Rousselot collagen production sites and is exclusively producing porcine collagen.
  • "We are excited to announce the commissioning of this production facility in Ghent," said Randall C. Stuewe, Chairman and Chief Executive Officer of Darling Ingredients.
  • The Company sells its products domestically and internationally and operates within three industry segments: Feed Ingredients, Food Ingredients and Fuel Ingredients.